News | EP Lab | August 15, 2019

Damaged Hearts Rewired With Nanotube Fibers

Texas Heart doctors confirm Rice-made, conductive carbon threads are electrical bridges

Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

August 15, 2019 — Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the electrical signals needed to keep those hearts beating.

Scientists at Texas Heart Institute (THI) report they have used biocompatible fibers invented at Rice University in studies that showed sewing them directly into damaged tissue can restore electrical function to hearts.

"Instead of shocking and defibrillating, we are actually correcting diseased conduction of the largest major pumping chamber of the heart by creating a bridge to bypass and conduct over a scarred area of a damaged heart," said Mehdi Razavi, M.D., a cardiologist and director of Electrophysiology Clinical Research and Innovations at THI, who co-led the study with Rice chemical and biomolecular engineer Matteo Pasquali.

"Today there is no technology that treats the underlying cause of the No. 1 cause of sudden death, ventricular arrhythmias," Razavi said. "These arrhythmias are caused by the disorganized firing of impulses from the heart's lower chambers and are challenging to treat in patients after a heart attack or with scarred heart tissue due to such other conditions as congestive heart failure or dilated cardiomyopathy."

Results of the studies on preclinical models appear as an open-access Editor's Pick in the American Heart Association's Circulation: Arrhythmia and Electrophysiology.1 The association helped fund the research with a 2015 grant.

The research springs from the pioneering 2013 invention by Pasquali's lab of a method to make conductive fibers out of carbon nanotubes. The lab's first threadlike fibers were a quarter of the width of a human hair, but contained tens of millions of microscopic nanotubes. The fibers are also being studied for electrical interfaces with the brain, for use in cochlear implants, as flexible antennas, and for automotive and aerospace applications.

The experiments showed the nontoxic, polymer-coated fibers, with their ends stripped to serve as electrodes, were effective in restoring function during month-long tests in large preclinical models as well as rodents, whether the initial conduction was slowed, severed or blocked, according to the researchers. The fibers served their purpose with or without the presence of a pacemaker, they found.

In the rodents, they wrote, conduction disappeared when the fibers were removed.

"The reestablishment of cardiac conduction with carbon nanotube fibers has the potential to revolutionize therapy for cardiac electrical disturbances, one of the most common causes of death in the United States," said co-lead author Mark McCauley, who carried out many of the experiments as a postdoctoral fellow at THI. He is now an assistant professor of clinical medicine at the University of Illinois College of Medicine.

"Our experiments provided the first scientific support for using a synthetic material-based treatment rather than a drug to treat the leading cause of sudden death in the U.S. and many developing countries around the world," Razavi added.

Many questions remain before the procedure can move toward human testing, Pasquali said. The researchers must establish a way to sew the fibers in place using a minimally invasive catheter, and make sure the fibers are strong and flexible enough to serve a constantly beating heart over the long term. He said they must also determine how long and wide fibers should be, precisely how much electricity they need to carry and how they would perform in the growing hearts of young patients.

"Flexibility is important because the heart is continuously pulsating and moving, so anything that's attached to the heart's surface is going to be deformed and flexed," said Pasquali, who has appointments at Rice's Brown School of Engineering and Wiess School of Natural Sciences.

"Good interfacial contact is also critical to pick up and deliver the electrical signal," he said. "In the past, multiple materials had to be combined to attain both electrical conductivity and effective contacts. These fibers have both properties built in by design, which greatly simplifies device construction and lowers risks of long-term failure due to delamination of multiple layers or coatings."

Razavi noted that while there are many effective antiarrhythmic drugs available, they are often contraindicated in patients after a heart attack. "What is really needed therapeutically is to increase conduction," he said. “Carbon nanotube fibers have the conductive properties of metal but are flexible enough to allow us to navigate and deliver energy to a very specific area of a delicate, damaged heart."

For more information: www.ahajournals.org/journal/circep

 

Reference

1. McCauley M.D., Vitale F., Yan J.S., et al. In Vivo Restoration of Myocardial Conduction With Carbon Nanotube Fibers. Circulation: Arrhythmia and Electrophysiology, Aug. 12, 2019. https://doi.org/10.1161/CIRCEP.119.007256

Related Content

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati
Medtronic Cobalt and Crome ICD
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received FDA approval for its Cobalt and Crome implantable cardioverter-defibrillators (
The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time. FDA clears, approved, the HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation.

The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time.

News | EP Lab | May 12, 2020
May 12, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the next-generation CardioFocus Inc.
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to edu
The European Heart Rhythm Association (EHRA) electrophysiology (EP) annual meeting cancelled due to coronavirus. #COVID19 #coronavirus #2019nCoV
Feature | EP Lab | March 10, 2020 | Dave Fornell, Editor
March 10, 2020 — Novel coronavirus (...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical SuperMap, an addition to its AcQMap 3-D imaging and mapping system used to guide electrophysiology (EP) catheter ablation procedures. Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in less than three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation, making it practical to execute an iterative "map, ablate, re-map" approach.
News | EP Lab | March 05, 2020
March 5, 2020 — The U.S.